Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Trial ID or NCT#
NCT05415696
Status
RECRUITING
Purpose
The purpose of this study is to learn if the prostatic artery embolization procedure can reduce urinary tract symptoms in patients with enlarged prostates and prostate cancer.
Official Title
Prostatic Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Undergoing Radiation Therapy
Eligibility Criteria
Ages Eligible for Study: 40 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Age ≥ 40 years and ≤ 90 years old - Prostate volume ≥ 40 mL and ≤ 300 mL - Biopsy proven prostate cancer undergoing radiation therapy - Diagnosis of moderate to severe lower urinary tract symptoms (LUTS) defined as at least one of the following: 1. IPSS ≥ 12 or dependent on urinary catheterization, or 2. IPSS Quality of Life (QoL) assessment ≥ 3, and 3. Qmax ≤ 12 mL/sec - Ability to understand and willingness to sign the written consent
Exclusion Criteria:
- - Neurogenic bladder disorder due to multiple sclerosis, Parkinson's disease, spinal cord injury, diabetes, etc., as demonstrated on urodynamic testing. - Detrusor muscle failure, urethral stenosis, or urinary obstruction due to causes other than prostatic obstruction, as demonstrated on urodynamic testing - Bladder diverticula greater than 5 cm or bladder stones greater than 2 cm - Other active urogenital cancer - Baseline serum creatinine greater than 2 mg/dL - Evidence of tortuous or atherosclerotic blood vessels - Coagulation disturbances not normalized by medical treatment - Allergy to iodinated contrast agents not responsive to steroid premedication regimen
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Moonkyung Patricia Kim
650-724-0201
View on ClinicalTrials.gov
